Developmental Determinants of Cardiovascular Disease
心血管疾病的发育决定因素
基本信息
- 批准号:10164843
- 负责人:
- 金额:$ 34.95万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-07-01 至 2022-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
This is the first renewal of the T32 application from Division of Pediatric Cardiology, Vanderbilt University
School of Medicine. By advancing a program that integrates formal training in research on developmental
determinants of cardiovascular disease with clinical training in pediatric cardiology, we will provide a unique
training environment that will foster development of academic pediatric cardiologists. This training program will
not only focus on the molecular and genetic etiologies of congenital heart disease, but will also emphasize the
impact of pre- and postnatal development in defining the manifestations of cardiovascular pathology after birth.
In addition to trainees in the Pediatric Cardiology, clinical or Ph.D. post-doctoral fellows who have an
expressed interest in investigating development mechanisms of cardiovascular disease will be eligible for
support. We are requesting continued support for 3 trainees / year for two years for a total of 6 trainees / year
for a five year period. This program will provide a unique opportunity for trainees to study the recapitulation of
normal developmental processes in the ontogeny of cardiovascular pathology presenting later in childhood or
adulthood. The program will be composed of two tracks optimized either for pursuit of preparation for (1) basic
science investigation or (2) clinical or translational research. A focused, mentored, laboratory experience with
targeted didactic interactions will be tailored to meet the needs of those pursing a more basic science career.
For trainees pursuing a career in clinical or translational medicine, the Vanderbilt Master of Science in Clinical
Investigation (MSCI) program will be an integral part of the training program. Candidates will be identified from
the pool of applicants applying for a pediatric cardiology fellowship (112 applicants for 3 positions in 2017) as
well as from talented clinical and post-doctoral fellows throughout Vanderbilt University. During a first clinical
year of pediatric cardiology fellowship (PGY-4) the candidates will be matched with mentors and together, they
will decide upon a research project. During the second and third years of a four year fellowship, trainees will
carry out a mentored research project. During the fourth year, the trainee will complete clinical training with the
option of advanced training in a sub-subspecialty as well as continued research and submission of a K08 or
K23 application. This grant will provide support for the second and third years of protected research training.
The Department of Pediatrics is committed to complete support of fellows during the first and fourth years as
well as supplementing support provided by this grant in years two and three. Using the unique strengths of
Vanderbilt University in the areas of cardiac development and regeneration, myocardial biology, pulmonary
biology and pulmonary hypertension, cardiovascular genetics and pharmacogenomics, vascular biology and
atherosclerosis, as well as cardiovascular outcomes based research and bioinformatics, the program will help
train the next generation of physician scientists focused on pediatric cardiovascular disease.
这是范德比尔特大学儿科心脏病科首次更新 T32 申请
医学院。通过推进一项将正规培训纳入发展研究的计划
通过儿科心脏病学的临床培训,我们将提供独特的心血管疾病的决定因素
将促进学术儿科心脏病专家发展的培训环境。本次培训计划将
不仅关注先天性心脏病的分子和遗传病因,还将强调
产前和产后发育对定义出生后心血管病理表现的影响。
除了儿科心脏病学、临床或博士学位的学员外。博士后研究员
表示有兴趣研究心血管疾病的发展机制将有资格
支持。我们请求持续为 3 名学员/年提供支持,为期两年,总共 6 名学员/年
为期五年。该计划将为学员提供一个独特的机会来学习重述
心血管病理学个体发育中的正常发育过程出现在儿童后期或
成年期。该计划将由两条经过优化的轨道组成,以追求 (1) 基础课程的准备
科学研究或 (2) 临床或转化研究。专注、受指导的实验室经验
将量身定制有针对性的教学互动,以满足那些追求更基础科学职业的人的需求。
对于追求临床或转化医学职业的学员来说,范德比尔特临床理学硕士
调查(MSCI)计划将成为培训计划的一个组成部分。候选人将被确定为
申请儿科心脏病学奖学金的申请人总数(2017 年 3 个职位有 112 名申请人)为
以及范德比尔特大学才华横溢的临床和博士后研究员。在第一次临床期间
儿科心脏病学奖学金 (PGY-4) 年,候选人将与导师匹配,他们一起
将决定一个研究项目。在四年奖学金的第二年和第三年,学员将
开展指导研究项目。在第四年中,学员将完成临床培训
选择子专业的高级培训以及继续研究和提交 K08 或
K23应用程序。这笔赠款将为第二年和第三年的受保护研究培训提供支持。
儿科致力于在第一年和第四年为研究员提供全面支持
以及补充第二年和第三年这笔赠款提供的支持。利用独特的优势
范德比尔特大学在心脏发育和再生、心肌生物学、肺脏等领域
生物学和肺动脉高压、心血管遗传学和药物基因组学、血管生物学和
动脉粥样硬化以及基于研究和生物信息学的心血管结果,该计划将帮助
培养专注于儿科心血管疾病的下一代医师科学家。
项目成果
期刊论文数量(19)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
H Scott Baldwin其他文献
H Scott Baldwin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('H Scott Baldwin', 18)}}的其他基金
The Role of Tie1 in Gut and Mesenteric Lymphatic Function
Tie1 在肠道和肠系膜淋巴功能中的作用
- 批准号:
10045453 - 财政年份:2020
- 资助金额:
$ 34.95万 - 项目类别:
The Role of Tie1 in Gut and Mesenteric Lymphatic Function
Tie1 在肠道和肠系膜淋巴功能中的作用
- 批准号:
10190937 - 财政年份:2020
- 资助金额:
$ 34.95万 - 项目类别:
The Role of Tie1 in Gut and Mesenteric Lymphatic Function
Tie1 在肠道和肠系膜淋巴功能中的作用
- 批准号:
10614926 - 财政年份:2020
- 资助金额:
$ 34.95万 - 项目类别:
The Role of Tie1 in Gut and Mesenteric Lymphatic Function
Tie1 在肠道和肠系膜淋巴功能中的作用
- 批准号:
10390364 - 财政年份:2020
- 资助金额:
$ 34.95万 - 项目类别:
Leveraging existing registry resources to facilitate clinical trials
利用现有注册资源促进临床试验
- 批准号:
9352386 - 财政年份:2016
- 资助金额:
$ 34.95万 - 项目类别:
相似国自然基金
水稻边界发育缺陷突变体abnormal boundary development(abd)的基因克隆与功能分析
- 批准号:32070202
- 批准年份:2020
- 资助金额:58 万元
- 项目类别:面上项目
Development of a Linear Stochastic Model for Wind Field Reconstruction from Limited Measurement Data
- 批准号:
- 批准年份:2020
- 资助金额:40 万元
- 项目类别:
相似海外基金
Development of a predictive tool for patients with cardiovascular diseases
开发心血管疾病患者的预测工具
- 批准号:
573792-2022 - 财政年份:2022
- 资助金额:
$ 34.95万 - 项目类别:
University Undergraduate Student Research Awards
Development of a Gectosome Therapy for Cardiovascular Diseases
心血管疾病的基因组疗法的开发
- 批准号:
10384422 - 财政年份:2022
- 资助金额:
$ 34.95万 - 项目类别:
Development of gene editing based therapy for cardiovascular diseases
开发基于基因编辑的心血管疾病疗法
- 批准号:
10652321 - 财政年份:2021
- 资助金额:
$ 34.95万 - 项目类别:
Development of gene editing based therapy for cardiovascular diseases
开发基于基因编辑的心血管疾病疗法
- 批准号:
10313701 - 财政年份:2021
- 资助金额:
$ 34.95万 - 项目类别:
Development of gene editing based therapy for cardiovascular diseases
开发基于基因编辑的心血管疾病疗法
- 批准号:
10441548 - 财政年份:2021
- 资助金额:
$ 34.95万 - 项目类别:
Development of a bacteria-derived ACE2-like enzyme as a therapeutics for treating cardiovascular diseases
开发一种细菌衍生的 ACE2 样酶作为治疗心血管疾病的药物
- 批准号:
20K21566 - 财政年份:2020
- 资助金额:
$ 34.95万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Development of sEH inhibitory vaccine for the treatment of cardiovascular diseases
开发治疗心血管疾病的sEH抑制疫苗
- 批准号:
19K17569 - 财政年份:2019
- 资助金额:
$ 34.95万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Respiratory modulation: Role in the development of cardiovascular diseases
呼吸调节:在心血管疾病发展中的作用
- 批准号:
nhmrc : GNT1156727 - 财政年份:2019
- 资助金额:
$ 34.95万 - 项目类别:
Project Grants
Development of novel therapies for cardiovascular diseases by targeting immunosenescence
通过靶向免疫衰老开发心血管疾病新疗法
- 批准号:
18K15197 - 财政年份:2018
- 资助金额:
$ 34.95万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Research for development of gut microbial drugs for preventing cardiovascular diseases.
预防心血管疾病的肠道微生物药物开发研究。
- 批准号:
17K09497 - 财政年份:2017
- 资助金额:
$ 34.95万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




